NCT01495221

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Vitreous -Retina- Macula Consultants of New York · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This is an open label study to evaluate intravitreally administered 2.0 mg intravitreal aflibercept injection in patients who have been previously treated for AMD and have persistent or recurrent fluid despite monthly intravitreal anti-VEGF therapy.

Conditions

• AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)

Interventions

Type	Name	Description
DRUG	Alfilbercept	All patients will receive 2.0 mg intravitreal aflibercept injection.

Timeline

• Start date: 2011-12-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2011-12-19
• Last updated: 2018-09-07
• Results posted: 2018-09-07

Locations

1 site across 1 country: United States